MNKD Earnings Prediction
The chart below shows how MNKD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MNKD sees a -1.14% change in stock price 10 days leading up to the earnings, and a +4.82% change 10 days following the report. On the earnings day itself, the stock moves by -0.59%. This data can give you a slight idea of what to expect for the next quarter's release.
MNKD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
76.78M
31.30%
9.56%
Gross Margin
77.07%
11.53%
3.16%
Operating Margin
31.34%
72.29%
41.55%
Net Margin
9.67%
302.92%
-41.32%
EPS
0.03
200.00%
-25.00%
No Data Available
MNKD Earnings Analysis
MannKind Corp Corporation (MNKD.O) Earnings Conference Call
Positive
Endocrine Business Revenue Surge: Record revenues in the endocrine business unit with Q4 revenue of $23 million and full year at $82 million.
Leadership Appointment for Growth: Appointment of Dominic Marasco as President of the Endocrine Business Unit to drive growth strategy.
Market Expansion Approval: Approval in India expected to launch in the second half of the year, expanding market reach.
Pediatric Indication Collaboration: Collaboration with Amphastar to promote pediatric indication, with filing expected in the first half of 2025 and approval in early 2026.
Tyvaso DPI Revenue Milestone: Tyvaso DPI collaboration generated over $200 million in revenues for 2024, marking a significant milestone for the Technosphere platform.
Clofazamine Study Progress: Clofazamine inhalation suspension Phase III study is progressing well, with 70% of sites activated and on track for interim readout in 2026.
Pediatric Revenue Growth: Afrezza revenue increased by 17% year-over-year, with projected sales run rate of over $200 million annually due to pediatric opportunities.
Q4 Revenue Surge: Strong financial performance with Q4 revenues of $77 million, a 31% increase year-over-year, and full year revenues of $286 million, a 43% increase.
Profitability Turnaround: Net income of $28 million for 2024 compared to a net loss of $12 million in 2023, indicating a turnaround in profitability.
Debt Reduction Achievement: Debt reduction of $236 million in 2024, resulting in a remaining debt balance of just $36 million, strengthening the balance sheet.
Negative
Revenue Growth Challenges: Afrezza revenue growth is hindered by competition from GLP-1 drugs and insulin pumps, which may limit market share expansion.
V-Go Sales Decline: V-Go product has reached peak sales and is no longer actively promoted, leading to a decline in revenue for the year.
Diabetes Segment Performance Issues: Despite a strong overall revenue increase, the diabetes segment's growth is not as robust as anticipated, particularly with V-Go's performance.
Pediatric Opportunity Challenges: The company faces challenges in scaling up the pediatric opportunity for Afrezza, with no immediate changes expected in the first half of 2025.
Clofazamine Pipeline Uncertainty: The pipeline for clofazamine inhalation suspension is still in early stages, with uncertainty around the interim analysis and potential need for trial size adjustments.
Product Revenue Dependence: The company has a significant reliance on Tyvaso DPI revenues, which may not be sustainable in the long term as it is dependent on a single product's success.
MNKD FAQs
How does MNKD typically perform around its earnings report dates?
Is MannKind Corp (MNKD) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MNKD Earning Call Sentiment
MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript
MNKD.O
-4.47%Positive
The earnings call highlights strong financial performance with a 43% increase in annual revenue and a shift to net income. Debt reduction and a strong cash position further strengthen the financial health. The Q&A section indicates steady margins and a focus on growth in pediatric diabetes. Despite some uncertainties in product adoption and study timelines, the overall sentiment is positive, driven by robust revenue growth, debt reduction, and promising future projections. The market cap suggests a moderate reaction, leading to a positive prediction for the stock price.
